Overview

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2022-11-11
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo. The study will look at different doses of the study drug, and whether there are differences when the drug is given once daily or twice daily.
Phase:
Phase 2
Details
Lead Sponsor:
Evelo Biosciences, Inc.